Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement

NCT05727176 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Cholangiocarcinoma
FGFR2 Fusions
Gene Rearrangement

Interventions

DRUG: TAS-120

Sponsor

Taiho Oncology, Inc.